Patent intelligence · US
US 12390509
Pharmaceutical composition comprising frataxin fusion protein and methods of use thereof
Pharmaceutical composition comprising frataxin fusion protein and methods of use thereof
Patent details — US 12390509
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 19, 2025
- Expiration
- Aug 14, 2045
- Applicant
- Larimar Therapeutics, Inc.
- Claims
- 56
- CPC classes
- A61K, A61K38/1709, A61K47/02, A61K47/10
Quick answer
US 12390509 (Pharmaceutical composition comprising frataxin fusion protein and methods of use thereof) is held by Larimar Therapeutics, Inc.. Status: granted. Granted Aug 19, 2025. Expires Aug 14, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Larimar Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 56
- CPC classes
- A61K, A61K38/1709, A61K47/02, A61K47/10, A61K47/12, A61K47/18
More from Larimar Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12351611
Molecules for organelle-specific protein delivery
granted -
US 12091437
Molecules for organelle-specific protein delivery
granted -
US 11976100
Methods for treating myelin associated diseases and mitochondria associated diseases
granted -
US 11891420
Molecules for organelle-specific protein delivery
granted
Frequently asked questions
What is US patent 12390509?
US 12390509 (Pharmaceutical composition comprising frataxin fusion protein and methods of use thereof) is held by Larimar Therapeutics, Inc.. Status: granted. Granted Aug 19, 2025. Expires Aug 14, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12390509?
Larimar Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 5 pharmaceutical patents for this assignee.
When does US 12390509 expire?
Our index shows an expiration date of Aug 14, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.